PL1896590T3 - Wolna od surowicy stabilna transfekcja i wytwarzanie rekombinowanych ludzkich białek w ludzkich liniach komórkowych - Google Patents

Wolna od surowicy stabilna transfekcja i wytwarzanie rekombinowanych ludzkich białek w ludzkich liniach komórkowych

Info

Publication number
PL1896590T3
PL1896590T3 PL06777525.4T PL06777525T PL1896590T3 PL 1896590 T3 PL1896590 T3 PL 1896590T3 PL 06777525 T PL06777525 T PL 06777525T PL 1896590 T3 PL1896590 T3 PL 1896590T3
Authority
PL
Poland
Prior art keywords
serum
production
cell lines
stable transfection
free stable
Prior art date
Application number
PL06777525.4T
Other languages
English (en)
Inventor
Haiyan Ding
Cathleen Wegmann
Carola Jüstel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35427852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1896590(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL1896590T3 publication Critical patent/PL1896590T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/007—Vectors comprising a special origin of replication system tissue or cell-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL06777525.4T 2005-06-30 2006-06-29 Wolna od surowicy stabilna transfekcja i wytwarzanie rekombinowanych ludzkich białek w ludzkich liniach komórkowych PL1896590T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05105965A EP1739179A1 (en) 2005-06-30 2005-06-30 Serum-free stable transfection and production of recombinant human proteins in human cell lines

Publications (1)

Publication Number Publication Date
PL1896590T3 true PL1896590T3 (pl) 2016-10-31

Family

ID=35427852

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06777525.4T PL1896590T3 (pl) 2005-06-30 2006-06-29 Wolna od surowicy stabilna transfekcja i wytwarzanie rekombinowanych ludzkich białek w ludzkich liniach komórkowych

Country Status (20)

Country Link
US (4) US8871439B2 (pl)
EP (2) EP1739179A1 (pl)
JP (3) JP5925407B2 (pl)
KR (1) KR101320489B1 (pl)
CN (2) CN105755041A (pl)
AU (1) AU2006265173B2 (pl)
BR (1) BRPI0613721B1 (pl)
CA (1) CA2611708C (pl)
DK (1) DK1896590T3 (pl)
ES (1) ES2574584T3 (pl)
HU (1) HUE028028T2 (pl)
IL (3) IL266122B2 (pl)
MX (1) MX2007015370A (pl)
NO (1) NO343221B1 (pl)
PL (1) PL1896590T3 (pl)
RU (1) RU2453597C2 (pl)
SI (1) SI1896590T1 (pl)
UA (1) UA99700C2 (pl)
WO (1) WO2007003582A2 (pl)
ZA (1) ZA200711013B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2164971B1 (en) * 2007-06-15 2015-12-09 Mogam Biotechnology Research Institute Method for manufacturing active recombinant blood coagulation factor ix
EP2300497B1 (en) 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
MX2011001624A (es) * 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
JP5592080B2 (ja) * 2009-05-08 2014-09-17 株式会社日立製作所 細胞培養方法、細胞培養システム
CN101906438B (zh) * 2009-06-05 2013-04-24 苏州泽璟生物制药有限公司 一种重组人凝血因子ⅶ在动物细胞内的表达和生产方法
WO2011060242A2 (en) 2009-11-13 2011-05-19 Talecris Biotherapeutics, Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
KR101951446B1 (ko) 2010-03-30 2019-02-22 옥타파마 아게 성장 인자 단백질을 정제하는 방법
WO2011121020A1 (en) 2010-03-30 2011-10-06 Octapharma Ag A process for purifying vitamin k dependent proteins such as coagulation factor ix
CA2796729C (en) 2010-04-20 2020-06-23 Octapharma Ag Melezitose for stabilizing human blood plasma proteins
ES2970057T3 (es) 2011-05-13 2024-05-24 Octapharma Ag Un procedimiento para aumentar la productividad de células eucarióticas en la producción de FVIII recombinante
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
CN103031277B (zh) * 2011-09-29 2015-07-15 重庆大学 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用
CN103305540B (zh) * 2012-03-14 2015-03-25 齐鲁制药有限公司 一种用于生物学活性测定的质粒及其制备方法
JP6473079B2 (ja) 2012-05-02 2019-02-20 ライフ テクノロジーズ コーポレーション 高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現
US9873891B2 (en) * 2013-05-03 2018-01-23 Fujifilm Diosynth Biotechnologies Uk Limited Expression process
EP3044231B1 (en) 2013-09-12 2020-08-05 BioMarin Pharmaceutical Inc. Aav vectors comprising a gene encoding factor viii
RU2695428C2 (ru) 2014-01-20 2019-07-23 Октафарма Аг СПОСОБ ПРОИЗВОДСТВА ФАКТОРА VIII, ИМЕЮЩЕГО УЛУЧШЕННОЕ СООТНОШЕНИЕ FVIII:C/FVIII:Ag
AU2015338923B2 (en) * 2014-11-02 2021-10-21 Arcturus Therapeutics, Inc. Messenger UNA molecules and uses thereof
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
US12099106B2 (en) 2018-05-04 2024-09-24 Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung eingetragener Verein Arterial spin labeling with evaluation of inversion state of magnetization
JP7497356B2 (ja) * 2018-12-06 2024-06-10 ビーエーエスエフ ソシエタス・ヨーロピア ゼオライト材料およびジルコニウムキレート錯体を含む水性懸濁液
CN110438066B (zh) * 2019-08-19 2021-01-12 杭州百凌生物科技有限公司 一种可稳定传代的可悬浮培养的哺乳动物细胞系293 c18p及其制备方法和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577259B2 (en) 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
DE10399009I1 (de) 1984-01-12 2003-10-23 Chiron Corp F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
JPS6171774A (ja) 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
FI98829C (fi) 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
EP0251843A1 (fr) 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
DK155388C (da) 1986-07-08 1989-10-23 Palle Pedersen Laas
EP0254076B1 (en) 1986-07-11 1991-05-08 Miles Inc. Improved recombinant protein production
NO872932L (no) 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
IL84168A0 (en) 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
EP0294910B1 (en) 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JPH084495B2 (ja) * 1988-08-19 1996-01-24 帝人株式会社 接着性動物細胞の培養方法
KR960701899A (ko) 1989-11-17 1996-03-28 안네 제케르 인자 viii:c활성을 갖는 단백질 복합체 및 그의 제조
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4204694C3 (de) 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
CN1064552C (zh) 1993-02-09 2001-04-18 奥克塔法马有限公司 失活无脂质被膜病毒的方法
US5585237A (en) * 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
US6136865A (en) 1995-05-20 2000-10-24 Octapharma Ag Method for reduction of the infectiousness of potentially infectious material
EP1036177A1 (en) * 1997-12-05 2000-09-20 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
ES2226383T3 (es) * 1998-04-17 2005-03-16 Societe Des Produits Nestle S.A. Linea de celulas inmortalizadas derivadas de tejidos cutaneos humanos normales.
US6210924B1 (en) * 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
CA2252972C (en) 1998-11-26 2012-09-18 National Research Council Of Canada Serum-free production of recombinant proteins and adenoviral vectors
EP1010762A1 (en) * 1998-12-02 2000-06-21 Aventis Behring Gesellschaft mit beschränkter Haftung DNA constructs of blood clotting factors and P-Selectin
HK1048138B (zh) * 1999-04-15 2009-06-12 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
EP1179017A1 (en) * 1999-04-29 2002-02-13 Novo Nordisk A/S Expression of heparin-binding protein in recombinant mammalian cells
EP1210411B1 (en) * 1999-08-25 2006-10-18 Immunex Corporation Compositions and methods for improved cell culture
EE200200538A (et) 2000-03-22 2004-04-15 Octagene Gmbh Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides
EP1301484A2 (en) * 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin receptor ligands
KR20040032105A (ko) * 2001-06-04 2004-04-14 엠엘 래보러토리즈 피엘씨 재조합 단백질의 조성물 및 재조합 단백질의 고수준대규모 생산방법
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
JP4344325B2 (ja) 2002-11-29 2009-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法
US7217566B2 (en) * 2003-03-24 2007-05-15 Invitrogen Corporation Attached cell lines
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
KR20130065723A (ko) * 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
JP2005073509A (ja) * 2003-08-28 2005-03-24 Nihon Pharmaceutical Co Ltd ヒトアンチトロンビンの生産方法
AU2004278634B2 (en) * 2003-10-03 2009-10-01 Keiichi Fukuda Method of inducing the differentiation of stem cells into cardiomyocytes
JP4705473B2 (ja) * 2003-11-06 2011-06-22 株式会社リプロセル 幹細胞の凍結保存法およびシステム
WO2005045021A1 (en) * 2003-11-06 2005-05-19 Exonhit Therapeutics Sa Bace455, an alternative splice variant of the human beta-secretase
BRPI0908886A2 (pt) 2008-02-15 2015-09-15 Koninkl Philips Electronics Nv aparelho, método e programa de computador pra segmentar um objeto, e, modelo de objeto

Also Published As

Publication number Publication date
US20160177362A1 (en) 2016-06-23
AU2006265173A1 (en) 2007-01-11
WO2007003582A3 (en) 2007-05-18
IL266122A (en) 2019-06-30
EP1896590A2 (en) 2008-03-12
JP2016154537A (ja) 2016-09-01
US20170152523A1 (en) 2017-06-01
IL187676A (en) 2017-02-28
ES2574584T3 (es) 2016-06-20
BRPI0613721A2 (pt) 2011-02-08
CN105755041A (zh) 2016-07-13
MX2007015370A (es) 2008-02-11
JP5925407B2 (ja) 2016-05-25
US8871439B2 (en) 2014-10-28
IL266122B2 (en) 2025-07-01
KR20080028891A (ko) 2008-04-02
RU2008103319A (ru) 2009-08-10
CA2611708A1 (en) 2007-01-11
EP1896590B1 (en) 2016-03-23
US20150044720A1 (en) 2015-02-12
JP2019058173A (ja) 2019-04-18
JP2008544750A (ja) 2008-12-11
SI1896590T1 (sl) 2016-07-29
BRPI0613721B1 (pt) 2022-05-24
NO343221B1 (no) 2018-12-10
US20100184141A1 (en) 2010-07-22
ZA200711013B (en) 2008-10-29
RU2453597C2 (ru) 2012-06-20
DK1896590T3 (da) 2016-06-13
JP6754414B2 (ja) 2020-09-09
EP1739179A1 (en) 2007-01-03
US9796986B2 (en) 2017-10-24
HUE028028T2 (en) 2016-11-28
IL187676A0 (en) 2008-08-07
UA99700C2 (ru) 2012-09-25
AU2006265173B2 (en) 2011-07-28
US9273325B2 (en) 2016-03-01
CA2611708C (en) 2019-11-12
IL266122B1 (en) 2025-03-01
IL250575A0 (en) 2017-03-30
KR101320489B1 (ko) 2013-10-30
WO2007003582A2 (en) 2007-01-11
CN101233238A (zh) 2008-07-30
NO20076087L (no) 2008-01-28
US9512457B2 (en) 2016-12-06

Similar Documents

Publication Publication Date Title
IL266122A (en) Stable serum-free cell-to-cell gene transfer and production of recombinant human proteins in human cell lines
ME03091B (me) Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima
IL262205A (en) Protein formulations and methods for their preparation
EP2102355A4 (en) PROTEINS AND PEPTIDES WITH EXTENDED ACTION AND METHODS OF PRODUCTION AND USE THEREOF
PT2115126E (pt) Utilização de cobre e glutamato na cultura de células para a produção de polipeptídeos
ZA200805920B (en) Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP2102237A4 (en) RECOMBINANT HUMAN FACTOR IX AND USE THEREOF
IL197917A0 (en) Genetic incorporation of unnatural amino acids into proteins in mammalian cells
EP1758617A4 (en) STABLE LIQUID AND LYOPHILIZED PROTEIN FORMULATIONS
EP2234636A4 (en) FORMULATIONS OF STABILIZED PEPTIDES AND PROTEINS
IL196565A0 (en) Physiologically active polypeptide polymer micelle having protein enclosed therein and process for the production thereof
EP2043677A4 (en) COMBINATIONS OF HUMAN PROTEINS TO INCREASE THE VITABILITY OF STEM CELLS AND PRECURSOR CELLS
EP2297331A4 (en) METHOD AND COMPOSITIONS FOR PRODUCING A RECOMBINANT PROTEIN IN MAMMALIAN CELLS WITH HBX EXPRESSION
IL207174A (en) An isolated peptide capable of stimulating the production of one or more extracellular matrix proteins in fibroblast cells, its pharmacological composition and its use
AU2003275326A8 (en) In vitro culture of tissue structures
EP1922328A4 (en) PEPTIDES TARGETED ON C PROTEIN KINASE ISOFORMS AND USE THEREOF
GB2442271B (en) An in vitro human skin assay protocol which directly uses the natural cellular interactions between un-manipulated autologous human epidermal and dermal cells
IL188824A (en) Plant cells expressing recombinant human glucosrybridosidase and their use as a drug
AU2004906554A0 (en) Derivation and culture of human embryo-derived cells
HK1120523A (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
GB0423516D0 (en) Improvements in and relating to polypeptide molecules and libraries of polypeptide molecules
AU2006901819A0 (en) In VIVO stimulation of cellular material
AU2005904150A0 (en) Delivery of proteins and peptides
AU2005901072A0 (en) Delivery of proteins and peptides
IL192438A0 (en) Stable enzymatic preparations and methods of use thereof